Search results
What Is Psoriatic Arthritis? 3 MDs Weigh In
PopSugar· 2 days agoPsoriasis affects about three percent of American adults, but the disorder can raise the risk of having more than skin scales and plaques. About 30 percent ...
Two Biosimilars Approved in Europe for Autoimmune Disorders
Medscape· 7 days agoThe drugs are intended to treat several types of arthritis, psoriasis, COVID-19, and Crohn's...
These Pictures Will Help You Identify the Most Common Skin Rashes
Prevention via Yahoo News· 7 days agoFrom eczema to allergic reactions to bug bites, here’s what common skin rashes look like in photos,...
Janssen-Cilag seeks expanded EMA approval for TREMFYA
Pharmaceutical Technology via Yahoo Finance· 18 hours agoGuselkumab has been approved in the EU to treat moderate to severe plaque psoriasis in adults who...
FDA OKs High-Concentration of Adalimumab Biosimilar Cyltezo
Medscape· 24 hours agoUnlike the low-concentration formulation of adalimumab-adbm, launched July 1, 2023, this high-concentration version has not yet been granted an interchangeability designation.
722 Shares in Amgen Inc. (NASDAQ:AMGN) Purchased by McAdam LLC
ETF DAILY NEWS· 1 day agoMcAdam LLC purchased a new position in Amgen Inc. (NASDAQ:AMGN – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission ...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ventyx...
Morningstar· 5 days agoPomerantz LLP announces that a class action lawsuit has been filed against Ventyx Biosciences, Inc. ("Ventyx" or the "Company") (NASDAQ: VTYX) and certain officers. The class action, filed in ...
Barrington Research Reaffirms Outperform Rating for Option Care Health (NASDAQ:OPCH)
ETF DAILY NEWS· 5 days agoBarrington Research restated their outperform rating on shares of Option Care Health (NASDAQ:OPCH –...
AbbVie (NYSE:ABBV) Price Target Cut to $187.00
ETF DAILY NEWS· 2 days agoAbbVie (NYSE:ABBV – Get Free Report) had its target price cut by equities researchers at Barclays from $195.00 to $187.00 in a research report issued on Monday, Benzinga reports. Barclays‘s ...
AbbVie (NYSE:ABBV) Shares Down 0.5% After Analyst Downgrade
ETF DAILY NEWS· 2 days agoAbbVie Inc. (NYSE:ABBV – Get Free Report) shares fell 0.5% on Monday after Barclays lowered their price target on the stock from $195.00 to $187.00. AbbVie traded as low as $158.56 and last ...